Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guohua Yu

Showing results (221-230 of 237) with videos related to

Pageof 24
Sort By:
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Ken Kato, Sung-Bae Kim, et al.
Cancer Communications (London, England)|October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II studyZhi Peng, Tianshu Liu, Jia Wei, et al.
BMC Medicine|May 5, 2023
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV studyJin Li, Shukui Qin, Lu Wen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2022
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 TrialAnwen Xiong, Shengxiang Ren, Huaimin Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II StudyLingfang Xia, Keqiang Zhang, Ying Tang, et al.
Theranostics|September 13, 2024
Extrachromosomal circular DNA orchestrates genome heterogeneity in urothelial bladder carcinomaWei Lv, Xiaoguang Pan, Peng Han, et al.
Cancer Communications (London, England)|October 26, 2021
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical studyJie Zhang, Yueyin Pan, Qin Shi, et al.
Theranostics|January 4, 2021
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinomaTao Jiang, Liyan Jiang, Xiaorong Dong, et al.
European Radiology|February 6, 2020
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trialZhigang Wei, Xia Yang, Xin Ye, et al.
Pageof 24

Showing results (221-230 of 237) with videos related to

Sort By:
Pageof 24
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Ken Kato, Sung-Bae Kim, et al.
Cancer Communications (London, England)|October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II studyZhi Peng, Tianshu Liu, Jia Wei, et al.
BMC Medicine|May 5, 2023
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV studyJin Li, Shukui Qin, Lu Wen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2022
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 TrialAnwen Xiong, Shengxiang Ren, Huaimin Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II StudyLingfang Xia, Keqiang Zhang, Ying Tang, et al.
Theranostics|September 13, 2024
Extrachromosomal circular DNA orchestrates genome heterogeneity in urothelial bladder carcinomaWei Lv, Xiaoguang Pan, Peng Han, et al.
Cancer Communications (London, England)|October 26, 2021
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical studyJie Zhang, Yueyin Pan, Qin Shi, et al.
Theranostics|January 4, 2021
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinomaTao Jiang, Liyan Jiang, Xiaorong Dong, et al.
European Radiology|February 6, 2020
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trialZhigang Wei, Xia Yang, Xin Ye, et al.
Pageof 24